AI News NQ Analysis

"Lypo-C CBD," Focused on Absorption Rate, to Launch for General Sale on Monday, September 8

NQ Score 45/100
N1 Content Completeness 8

AI Summary (NQ-processed)

SPIC Inc. will launch "Lypo-C CBD," a CBD supplement with enhanced absorption using liposome technology, for general sale starting September 8, 2025. The product was pre-released at medical institutions from June 2025 and received high praise from doctors and specialists. In response to customer requests to "try a small amount first," a new 9-sachet package will also be available. The product will be sold on e-commerce malls like Rakuten and Amazon, positioned as an accessible self-care option.

AI Analysis

Frequently Asked Questions

Q: Where is Lypo-C CBD manufactured?
A: The product is "MADE IN JAPAN" and manufactured domestically in Japan.
Q: What is the origin of the CBD raw material used?
A: The raw material is from Biosyyd in Lithuania, extracted from organically grown industrial hemp.
Q: Can this product be purchased overseas?
A: The article announces sales on e-commerce malls within Japan and does not mention international shipping. Details should be confirmed with each respective online store.
Q: Why are THC and CBN excluded?
A: THC is a psychoactive component regulated by Japanese law. CBN is also subject to regulatory trends. They are removed to comply with Japanese regulations and ensure consumer safety and peace of mind.
Q: What is broad-spectrum CBD?
A: It refers to CBD that contains various cannabinoids and terpenes found in hemp, except for THC. It is expected that multiple components work together to produce a synergistic effect (the entourage effect).